Fig. 1
Evidence network plot. BSC, Best Supportive Care; N, number of patients; RCT, Randomized Controlled Trial; REDo, regorafenib dose optimization; TAS-102, trifluridine/tipiracil; TAS-BEV, TAS-102 with bevacizumab
Fig. 1 | Health Economics Review